| INTRODUC TI ON
Kidney transplant is the best treatment option for patients with endstage renal disease. 1 The discovery and development of potent immunosuppressive drugs that are able to prevent or treat rejection have greatly improved short-term graft survival rates over the past 50 years. 2 Despite these advances, various large registries show graft failure rates of approximately 10% within the first year after transplant, increasing to up to 40% at 10 years after transplant. To further improve the outcome of kidney transplant, there is a clear need for parameters that enable risk stratification for graft failure. [2] [3] [4] [5] [6] [7] In the Eurotransplant region, the presence of donor-specific HLA antibodies (DSAs) against a potential donor kidney causing complement-mediated lysis 8 is considered a contraindication for transplant. These antibodies can be detected with the complementdependent cytotoxicity crossmatch assay (CDC-XM), which has been the gold standard since 1969. With the more recently developed single antigen bead (SAB) assays, DSAs can be detected with increased sensitivity and specificity, 9 but the relation between these SAB assay-detected antibodies and clinical outcome is still unclear.
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The presence of SAB assay-detected antibodies that do not cause a positive CDC-XM is not a contraindication for transplant but may indicate an increased immunological risk for rejection and allograft loss. 15 It is well known that graft survival rates in patients who received a living donor kidney are higher than the rates in recipients of a deceased donor kidney. 16 While recent large-cohort studies of the impact of DSAs on graft survival have mainly focused on deceased donor transplants, [17] [18] [19] the effect of SAB assay-detected DSAs on living donor transplants has not been studied in large cohorts. In a Japanese single-center study, 324 living donor kidney transplant recipients were analyzed to investigate the outcome of the 92 kidney transplant recipients with DSAs in combination with anti-blood type, anti-HLA antibodies, or both; all were desensitized before transplant. 20 The authors reported no significant difference in graft survival of the different groups compared with the no-DSAs group at 1 and 5 years after transplant. As far as we could find, there were no large cohorts describing the effect of pretransplant DSAs with negative CDC-XM in exclusively living donor kidney transplants without desensitization treatment. Orandi et al 21 studied the outcomes of incompatible living donor kidney transplants based on the risk determined by using the SAB assay, flow cytometry crossmatch (FCXM), or CDC-XM and found that patients with a positive SAB assay and a negative FCXM (n = 185) who were desensitized had similar graft survival as a large group of compatible patients (n = 9669), while patients with a positive FCXM (n = 536) or a positive CDC-XM (n = 304) experienced an increased risk of graft loss.
Another study about living donor transplants performed after a positive FCXM (n = 41) reported that the long-term survival was worse in desensitized recipients compared with matched recipients with a negative FCXM (n = 41).
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In a single-center study, including both living and deceased donor transplants, it was shown that patients with combined pretransplant HLA class I and II DSAs had an increased risk of graft loss. 23 As part 
| Detection and definition of DSAs
The presence of HLA antibodies (HLA-Abs) in the pretransplant sera, used for pretransplant crossmatch, was assessed retrospectively in a central laboratory as described previously. 25 In brief, sera were first tested for the presence of HLA class I and class II antibodies by 
| Statistical analysis
Differences in patient, donor, and transplant characteristics between the DSA-positive and -negative groups were assessed by using the χ 2 test for categorical variables and Mann-Whitney U test for continuous variables. Death-censored graft survival was assessed by using the adjusted Kaplan-Meier estimator (AKME) based on inverse probability weighting (IPW). 26 The following covariates were con- 
| RE SULTS

| Baseline characteristics
Patient, donor, and transplant characteristics stratified according to the presence of pretransplant DSAs are summarized in Table 1 . Of 4724 patients, 567 (12%) had pretransplant DSAs. The mean age at transplant was significantly lower in recipients with DSAs. The DSA group contained a higher proportion of female recipients (59% vs 38%),
and PRA values determined with CDC were clearly related to the presence of DSAs. Additionally, there were significantly more retransplants in the DSA (47.6%) group. In 33% of the transplants without DSAs, the kidney was donated by a living donor, whereas 24% of the transplants with preformed DSAs had living donors. Most patients initially received a triple immunosuppressive regimen consisting of steroids, cyclosporine or tacrolimus, and mycophenolate mofetil or azathioprine.
In addition, 26% of the patients received induction therapy, with either a T cell-depleting antibody (4%) or an IL-2 receptor-blocking antibody (22%). Minimal follow-up time was 10 years after transplant. 
| Impact of pretransplant DSAs on long-term graft survival
Using SAB assays, we determined the presence of antibodies against (Table S1 ). Donor-specific antibody prevalence against the donor HLA loci A, B, DR, and DQ is depicted in Figure 1B . In 4157 (88%) of the 4724 kidney transplants, recipients harbored no pretransplant DSAs against these antigens.
The AKME showed a 10-year death-censored graft survival of 78% (95% CI 77%-80%) for the 4157 patients without and 66% (95% CI 64%-67%) for the 567 patients with DSAs in pretransplant sera ( Figure 2A) . The multivariable analysis, adjusted for the same covariables, showed that the presence of DSAs was associated with a higher risk of graft failure (Table 2 ; HR 1.77, 95% CI 1.51-2.08).
Because our cohort contains a relatively high proportion of living donors, we analyzed the impact of DSAs on long-term graft survival according to donor status. For the living donor transplants (n = 1487), there was only a limited and nonsignificant relation between pretransplant DSAs and 10-year death-censored graft survival, which was 78% and 84% for patients with and without DSAs, respectively ( Figure 2B , P = .07). For the deceased donor transplants (n = 3237), the 10-year death-censored graft survival was 60% and 76% for patients with and without DSAs, respectively ( Figure 2C , P < .0001), demonstrating a clear adverse effect of pretransplant DSAs.
These findings were confirmed in a multivariable analysis ( Table 3 , the patient, donor, and transplant characteristics of living donor (n = 1487) and deceased donor (n = 3237) transplants are summarized. In addition, the characteristics for living and deceased donor transplants were further subdivided for transplants with DSAs (Table S2) , with class I DSAs only (Table S3) , with class II DSAs only (Table S4) , and with class I and II DSAs (Table S5 ).
| Impact of pretransplant DSAs on early and late graft failure
The effect of pretransplant DSAs on graft survival was already evident early after transplant ( Figure 3A,B) . In living donor transplants, 1-year death-censored graft survival for patients with and without DSAs was 94% and 96% ( Figure 3A) , respectively ( Table 2; 
| Effect of pretransplant HLA class I and II DSAs on graft survival
Next, we investigated separately the effects of donor-specific HLA class I (A/B) and HLA class II (DR/DQ) antibodies on kidney graft survival within the living donor transplants. We found no effect on graft survival within 1 year after transplant of pretransplant DSAs against either class I or II antigens only, and only a limited effect of 4% and 5% on the 10-year graft survival, respectively ( Figure 3E ; Table 2 ; HR 1.35, 95% CI 0.86-2.12). In contrast, in deceased donor transplant, the isolated presence of either class I or class II DSAs was clearly associated with an increased risk of graft failure (HR 1.93, 95% CI 1.51-2.48; HR 1.74, 95% CI 1.36-2.24, respectively) with a 10-year death-censored graft survival of 60% and 61%, respectively, compared with 76% in transplants with DSA-negative recipients ( Figure 3F ).
The combined presence of class I and II DSAs resulted in the poorest graft survival for both donor types, with a decrease from 84% to 75% at 10 years after transplant for living donor grafts (HR 2.84, 95% CI 1.05-7.69) and a decrease from 76% to 54% for deceased donor grafts (HR 1.90, 95% CI 1.25-2.88).
| D ISCUSS I ON
In this multicenter study, we found a limited effect of pretransplant SAB assay-defined DSAs on graft failure in living donor transplants.
In contrast, pretransplant SAB assay-defined DSAs are a clear risk factor for graft loss in deceased donor transplantations with a negative CDC-XM. Further subdivision of the DSAs in deceased donor transplantations revealed that DSAs against either class I or II did constitute a significant risk factor for graft loss and pretransplant DSAs against both HLA class I and class II resulted in the poorest death-censored graft survival. In living donor transplants, the combination of class I and II DSAs seem to be associated with an increased risk for graft failure, but this could not be assessed due to their low prevalence.
Recently published studies on pretransplant DSAs focused mainly on deceased donor transplants, as these are most prevalent in, for example, France, Germany, and the United States. [17] [18] [19] Studies on living donor transplant are scarce; in a single-center study, where 324 living donor transplants were analyzed, no significant difference in the 5-year graft survival of patients with DSAs was found compared with patients with anti-blood type antibody, anti-HLA-Abs, or no DSAs. 20 Mohan et al 19 reported a meta-analysis of DSAs detected with, among others, SAB assays and calculated an increased risk for graft failure in the presence of SAB assay-detected DSAs with negative CDC-XM, similar to our study. The effect of DSAs in living donor transplant has not been investigated so far in large cohorts. In The Netherlands, currently F I G U R E 2 Long-term graft survival of kidney transplants according to the presence of pretransplant donor-specific HLA antibodies (DSAs). A. Adjusted Kaplan-Meier estimates (AKME) for death-censored graft survival according to the presence of pretransplant DSAs for the total cohort including deceased-and living-donor transplants (N = 4724). B. AKME for death-censored graft survival according to the presence of pretransplant DSAs for living-donor transplants only (n = 1487). C. AKME for deathcensored graft survival according to the presence of pretransplant DSAs for deceased-donor transplants only (n = 3237). All AKME were adjusted for the same covariates: recipient age (quadratic) and donor age (quadratic) No DSA DSA
Deceased donors (N=3237)
Graft survival (%) (Table S7B -D). The higher "strength" of DSAs as expressed by these 3 parameters could (partly) explain the worse graft survival of this group. DSA class I and II positivity, however, provides a better risk classifier than we were able to construct from 3 DSA strength parameters in this study. Other studies have shown that DSA assessments using MFI alone may not be sufficient for assessing the potential risk for graft damage and decreased survival. Multiple assays are used, such as Flow-XM, 21, 27 C1q-SAB assays, 17 C3d-SAB assays, 28 or IgG-subclass analysis. 29 Our cohort includes 63 patients participating in the Eurotransplant Acceptable Mismatch program with an HLA antibody profile based on CDC, in some cases supplemented with solid phase assays. 30 Inclusion of this patient group did not induce bias as we observed no major impact on our conclusions if we excluded these patients from our cohort (data not shown). We excluded 46 transplants because the kidney failed during surgery or shortly thereafter due to technical nonimmunologic problems. The impact of inclusion and exclusion of these patients on graft survival was equal for both groups (DSAs versus no DSAs).
Our study has a few limitations. Because we collected sera retrospectively, we were able to collect 78% in total. We are mainly missing sera from older transplants of 4 centers, while from the other 3 centers we collected > 90%. Limited information was available on rejection and donor organ quality, and we do not have information on posttransplant (de novo) DSA formation. This is a retrospective cohort of kidney transplants between 1995 and 2005, so the registration of rejections was limited. We have information only on whether patients were treated for a rejection including the date of rejection and, if performed, the date of biopsy. At that time, biopsies
were not always performed, and, therefore, some of the registered rejections might not have been actual rejections. On the other hand, rejections might have been missed or not registered. Others have
shown that in living donor transplants, DSAs was an important predictor of antibody-mediated rejection, while this was not the case for graft failure. 31 Using the limited rejection data that we had, we observed that patients with pretransplant DSAs had a higher incidence of rejection in living as well as deceased donor transplants (data not shown).
For posttransplant DSAs determined using SAB assays, it was already shown that it has an adverse effect on graft survival.
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For our cohort, we can assess only the potential for confounding CI, confidence interval; DSA, donor-specific HLA antibody. In this multivariable analysis we adjusted for differences in the following covariates: recipient age (quadratic), donor age (quadratic), donor type (living or deceased), cold ischemia time in hours for donation after brain death (DBD) and donation after cardiac death (DCD), time on dialysis in years (quadratic), and induction therapy with interleukin-2 receptor-blocking antibody. The hazard ratios of the covariates are shown in Table S6 .
TA B L E 2 Multivariable analyses of DSAs using Cox proportional hazards model
by de novo DSAs via the average number of HLA mismatches.
Because the DSA-positive groups have fewer mismatches for all HLA loci (Table S9) , we expect to be underestimating rather than overestimating the effect of pretransplant DSAs in that respect. We also find fewer mismatches for all loci in deceased donor transplants. In addition, the difference in impact of DSAs on graft survival between living and deceased donor transplant is likely not due to difference in either DSA strength (Table S7a ) Figure S3 ; Figure S4 ). However, it is known that graft survival rates of poorly HLA-matched living donor grafts are superior to those of well HLA-matched deceased donor grafts. 16, 32 Interindividual differences in the level of HLA antigen expression on the cell surface have been shown to affect the CDC-XM, 34 indicating that sufficient HLA expression is required to induce effector mechanisms such as complement activation. The limited F I G U R E 3 Impact of donor-specific HLA antibodies (DSAs) on graft survival for deceased-donor transplants. A. Adjusted Kaplan-Meier estimates (AKME) for 1-year death-censored graft survival according to the presence of pretransplant DSAs for living-donor transplants only (n = 1487). B. AKME for 1-year death-censored graft survival according to the presence of pretransplant DSAs for deceased-donor transplants only (n = 3237). C. Analysis of long-term effect of pretransplant DSAs starting at 1 year after transplant for living-donor transplants only (n = 1417). D. Analysis of long-term effect of pretransplant DSAs starting at 1 year after transplant for deceased-donor transplants only (n = 2834). E. AKME for death-censored graft survival according to the presence of pretransplant HLA class I (A/B) and/ or II (DR/DQ) DSAs for living-donor transplants only (n = 1487). F. AKME for death-censored graft survival according to the presence of pretransplant HLA class I (A/B) and/or II (DR/DQ) DSAs for deceased-donor transplants only (n = 3237). All AKME were adjusted for the same covariates: recipient age (quadratic) and donor age (quadratic), donor type (living or deceased; for the total cohort only), cold ischemia time 1350  1308  1301  1298  1289  137  128  128  128  1 28 No DSA DSA
Living donors (N=1487) Early graft failure (<1Y)
impact of preformed DSAs against HLA class I or class II in living donor transplant compared with deceased donor transplant might be explained by a lower expression of HLA and adhesion molecules on the endothelial cells in living donor organs compared with those of deceased donors. 35 In our cohort of 1487 living donor kidney transplants, the combination of class I and II antibodies occurred in only 18 cases, indicating that the prevalence of this risk factor is relatively low.
In conclusion, our study demonstrated that in the presence of negative CDC-XM, SAB assay-defined DSAs against either HLA class I or HLA class II is a significant risk factor in deceased donor transplant, but this seems not to be the case in living donor transplant. The combined presence of DSAs against HLA class I and II has a much stronger negative impact on graft survival after deceased donor transplant, while in living donor transplants class I and II DSAs seem to be associated with an increased risk for graft failure.
However, this could not be assessed due to their low prevalence.
Based on these results, we suggest that the combination of class I and II DSAs be taken into account in the allocation of donor kidneys in Eurotransplant region. Moreover, recipients with this combination of DSAs should be considered as patients with a higher risk of graft failure.
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